Podcasts

In part 1 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses the current emerging therapies for platinum-resistant ovarian malignancies.

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.

Van Morris, MD, reviews emerging targeted therapies for patients with metastatic colorectal cancer.

Carla Casulo, MD, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed FL.

Connie Batlevi, MD, PhD, shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class oral selective EZH2 inhibitor, for patients with FL.

In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.

In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.